RT Journal Article
SR Electronic
T1 Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005007
DO 10.1136/jitc-2022-005007
VO 11
IS 1
A1 Rudin, Charles M
A1 Pandha, Hardev S
A1 Zibelman, Matthew
A1 Akerley, Wallace L
A1 Harrington, Kevin J
A1 Day, Daphne
A1 Hill, Andrew G
A1 O'Day, Steven J
A1 Clay, Timothy D
A1 Wright, Gavin M
A1 Jennens, Ross R
A1 Gerber, David E
A1 Rosenberg, Jonathan E
A1 Ralph, Christy
A1 Campbell, David C
A1 Curti, Brendan D
A1 Merchan, Jaime R
A1 Ren, Yixin
A1 Schmidt, Emmett V
A1 Guttman, Lisa
A1 Gupta, Sumati
YR 2023
UL http://jitc.bmj.com/content/11/1/e005007.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.